Tenax Therapeutics, Inc.
TENX
$1.83
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.64% | -10.98% | 118.77% | 329.86% | 321.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.29% | 46.17% | 125.48% | 263.84% | 221.22% |
| Operating Income | -59.29% | -46.17% | -125.48% | -263.84% | -221.22% |
| Income Before Tax | -64.13% | -51.00% | -147.97% | -298.99% | -203.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.13% | -51.00% | -147.97% | -298.99% | -203.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -64.13% | -51.00% | -147.97% | -298.99% | -203.41% |
| EBIT | -59.29% | -46.17% | -125.48% | -263.84% | -221.22% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -27.69% | -22.14% | -113.85% | -112.45% | 84.99% |
| Normalized Basic EPS | -27.67% | -22.16% | -113.87% | -112.39% | 84.99% |
| EPS Diluted | -27.69% | -22.14% | -113.85% | -112.45% | 84.99% |
| Normalized Diluted EPS | -27.67% | -22.16% | -113.87% | -112.39% | 84.99% |
| Average Basic Shares Outstanding | 28.55% | 23.62% | 15.93% | 87.80% | 1,920.85% |
| Average Diluted Shares Outstanding | 28.55% | 23.62% | 15.93% | 87.80% | 1,920.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |